4 completed, 2 terminated, 1 withdrawn. 7 Phase 1, 4 Phase 2.
By phase and status
Follow BL-8040: new trials by email Literature Review of BL-8040 trials Research Report on BL-8040
Trials (filtered) newest first · largest first
All 7 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization Motixafortide, G-CSF - Multiple Myeloma Phase 1 Completed 20 2024-10-31 2025-08-29 Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) Motixafortide, Natalizumab, Leukapheresis - Sickle Cell Disease Phase 1 Completed 10 2023-07-07 2025-08-11 Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML) BL-8040, Atezolizumab - Acute Myeloid Leukemia Phase 1 / Phase 2 Terminated 1 2018-01-08 2024-09-05 A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin - Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma Phase 1 / Phase 2 Terminated 219 2017-10-13 2026-08-03 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Nab-Paclitaxel, Gemcitabine, Oxaliplatin - Pancreatic Adenocarcinoma Phase 1 / Phase 2 Completed 341 2017-07-05 2025-11-21 Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia BL-8040 - Chronic Myeloid Leukemia Phase 1 / Phase 2 Withdrawn 2014-11-01 2016-08-15 A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers BL-8040, Placebo - Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB) Phase 1 Completed 33 2014-08-01 2015-07-31
Conditions studied Anemia, Sickle Cell (1) · Esophageal Neoplasms (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Multiple Myeloma (1)
Sponsors BioLineRx, Ltd. (2) · Hoffmann-La Roche (2) · Washington University School of Medicine (2) · Sheba Medical Center (1)
Countries United States (5) · Israel (4) · Spain (3) · South Korea (2) · Australia (1) · Czechia (1) · Germany (1) · Japan (1) · Poland (1) · Slovakia (1) · Taiwan (1) · United Kingdom (1)
Top investigators Zachary Crees, M.D. (2) · Arnon Aharon, MD (1) · Arnon Nagler, MD (1)
Results publications PMID 36940261 , PMID 39707623 , PMID 41449151
NIH funding 2016 (2)